• Recruiting

NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM

Updated: May 25

NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma


HDP 101

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.


Sponsor

Heidelberg Pharma AG


Multiple Locations

International Study

 

Official Title: A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma


First Posted : May 10, 2021


Click here for details on ClinicalTrials.gov

 

Drug: HDP-101

 

anti-BCMA/alpha-amanitin antibody-drug conjugate HDP-101

Anti-BCMA/Alpha-amanitin Antibody-drug Conjugate HDP-101 (Code C179409)

ADC HDP-101

Anti-BCMA Antibody-drug Conjugate HDP-101

Anti-BCMA/Alpha-amanitin ADC HDP-101

Anti-BCMA/Alpha-amanitin Antibody-drug Conjugate HDP-101

HDP 101

HDP-101

HDP101

 

Locations

United States, Georgia

United States, New York

United States, Texas

Europe

Germany











Posts Archive